|
|
 |
|
|
SCIENCE NEWS
Blood Stem Cell, Leukemia Link Illuminated in UCSF-Led Study
A UCSF-led team has discovered at least one key reason why blood stem cells are susceptible to developing the genetic mutations that can lead to adult leukemia. [Press release from the University of California discussing online prepublication in Cell Stem Cell]
Cancer's 'Addiction' Spurs New Treatment Hopes
Cancer can call upon a bewildering array of genetic tricks to wreak havoc, but researchers show that the disease can become dependent upon a tiny gene that allows it to adapt and proliferate. [Press release from Yale Cancer Center discussing online prepublication in Nature]
Chronic Health Conditions Common for Stem Cell Transplant Survivors
Although hematopoietic cell transplantation cures many blood diseases, two-thirds of long-term survivors report at least one chronic health condition after the procedure, according to a recent study. [Press release from the American Society of Hematology discussing online prepublication in Blood]
|
|
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)
LABORATORY RESEARCH
OncomiR Addiction in an In Vivo Model of MicroRNA-21-Induced Pre-B-Cell Lymphoma
Results demonstrate that tumors can become addicted to oncomiRs and support efforts to treat human cancers through pharmacological inactivation of microRNAs such as miR-21. [Nature]
Therapeutic Cell Engineering with Surface-Conjugated Synthetic Nanoparticles
Here, researchers describe a strategy to enhance cell therapy via the conjugation of adjuvant drug-loaded nanoparticles to the surfaces of therapeutic cells. [Nat Med]
Inducible fli-1 Gene Deletion in Adult Mice Modifies Several Myeloid Lineage Commitment Decisions and Accelerates Proliferation Arrest and Terminal Erythrocytic Differentiation
This study investigated the role of the ETS transcription factor Fli-1 in adult myelopoiesis using new transgenic mice allowing inducible fli-1 gene deletion. fli-1 deletion in adult induced mild thrombocytopenia associated with a drastic decrease in large mature megakaryocytes number. [Blood]
BMI1 Collaborates with BCR-ABL in Leukemic Transformation of Human CD34+ Cells
Here, researchers show that BMI1 collaborates with BCR-ABL in inducing a fatal leukemia in NOD-SCID mice transplanted with transduced human CD34+ cells within 4-5 months. [Blood]
Dose-Dependent Regulation of Primitive Erythroid Maturation and Identity by the Transcription Factor Eklf
Researchers conclude that Eklf gene dosage is crucial for regulating the surface phenotype and molecular identity of maturing primitive erythroid cells. [ Blood]
Developmentally Induced Mll1 Loss Reveals Defects in Postnatal Hematopoiesis
Researchers show that VavCre;Mll mutants exhibit phenotypically normal fetal haematopoiesis, but rarely survive past three weeks of age. [Leukemia]
Involvement of the SRF Coactivator Megakaryoblastic Leukemia in the Activin-Regulated Dendritic Complexity of Rat Cortical Neurons
Here, researchers individually knocked down the four transcription factors PU.1, IRF8, MYB and SP1 in the human monocyte leukemia THP-1 cell line and profiled the genome-wide transcriptional response of individual transcription starting sites using deep sequencing based Cap Analysis of Gene Expression. [ J Biol Chem]
CLINICAL RESEARCH
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
The results suggest that midostaurin has hematologic activity in both patients with FLT3-mutant and wild-type. The degree of clinical activity observed supports additional studies that combine midostaurin and other agents such as chemotherapy especially in FLT3-mutant acute myeloid leukemia. [J Clin Oncol]
Phase I/II Clinical Study of Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and Myelodysplasia
This Phase I/II study demonstrates that oral once daily dosing with 130 mg tosedostat is well tolerated and has significant antileukemic activity. The favorable risk-benefit profile suggests that further clinical trials are warranted. [J Clin Oncol]
LNK Mutation Studies in Blast-Phase Myeloproliferative Neoplasms, and in Chronic-Phase Disease with TET2, IDH, JAK2 or MPL Mutations
LNK mutation analysis was performed in 61 patients with blast-phase myeloproliferative neoplasms; post-primary myelofibrosis in 41, post-polycythemia vera in 11 and post-essential thrombocythemia in 9 patients. [Leukemia]
|
|
INDUSTRY NEWS
Stem Cell Agency Commits $243 Million, Expands Team Approach to Developing New Therapies
The Governing Board of the California Institute for Regenerative Medicine, the state stem cell agency created by proposition 71, approved the concept for up to $243 million round of funding to move stem cell-based therapies to clinical trial. [California Institute for Regenerative Medicine Press Release]
EpiCept Corporation Receives Refusal to File Letter from U.S. FDA on Ceplene New Drug Application
EpiCept Corporation announced that it received a refusal to file letter from the U.S. Food and Drug Administration on the New Drug Application for Ceplene(R) (histamine dihydrochloride). [EpiCept Corporation Press Release]
ASH Recommends Cross-Disciplinary Engagement to Advance Regenerative Medicine
The American Society of Hematology (ASH) has developed specific recommendations to the scientific community and federal agencies to help propel collaborative research in regenerative medicine in order to make real strides in improving patient care. [American Society of Hematology Press Release]
Seattle Genetics Data Could Make 2010 a Banner Year
Seattle Genetics, a developer of antibody-based drugs, could have important data as soon as this month from a trial of its experimental leukemia treatment, followed within weeks by results from two trials of another drug for lymphoma. [Reuters]
Sanofi Seeks Efficiencies with New Model
Sanofi-aventis is dividing its vast resources into decentralized disease-based units, each with its own departments for research and development, regulatory affairs, marketing, and sales -- a plan designed to identify promising drugs more quickly and weed out failures before spending billions on unsuccessful clinical trials. [The Boston Globe]
|
|
POLICY NEWS
Ipilimumab Receives FDA Priority Review Designation for Adult Patients with Previously Treated Advanced Melanoma
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the Biologics License Application for ipilimumab for the treatment of adult patients with advanced melanoma who have been previously treated. [Food and Drug Administration, United States]
Lawrence A. Tabak Named Principal Deputy Director NIH
National Institutes of Health Director Francis S. Collins, M.D., Ph.D., announced the appointment of Lawrence A. Tabak, D.D.S., Ph.D., as principal deputy director of the National Institutes of Health. [National Institutes of Health, United States]
FDA, Companies Must Stretch Overseas Supply Oversight
The FDA is trying to stretch its enforcement reach over foreign drug suppliers, potentially through consent decrees, and is asking manufacturers to take bigger steps as well to tighten the pharmaceutical supply chain. [Food and Drug Administration, United States]
Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA) (R01) (RFA-GM-11-003) [National Institutes of Health, United States]
Proposed Collection; Comment Request; STAR METRICS--Science and Technology in America's Reinvestment: Measuring the Effects of Research on Innovation, Competitiveness and Science (FR Doc. 2010-20614) [National Institutes of Health, United States]
National Heart, Lung, and Blood Institute; Notice of Closed Meetings (FR Doc. 2010-20291) [National Institutes of Health, United States]
Office of the Director, National Institutes of Health; Notice of Meeting (FR Doc. 2010-20675) [National Institutes of Health, United States]
NIH-RAID Updates on Program Scope and Procedures: Biologics Manufacture, Lead Selection, and Product Development Plans (NOT-RM-10-012) [National Institutes of Health, United States]
Support of National Institute of General Medical Sciences Program Project Grants (P01) (PAR-10-266) [National Institutes of Health, United States]
Complete List of Currently Approved NDA and ANDA Application Submissions (PDF - 62KB) [Food and Drug Administration, United States]
Complete List of Currently Approved Premarket Approvals (PMAs) (PDF - 27KB) [Food and Drug Administration, United States]
|
|
EVENTS (Listed by Date)
The European Molecular Biology Organization (EMBO) Meeting 2010
September 4-7, 2010
Barcelona, Spain
International Society for Cellular Therapy (ISCT) - Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy
Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States
Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia
Sickle Cell Disease Association of America (SCDAA) 38th Annual Convention
September 21-24, 2010
Washington D.C., United States
American Society of Hematology (ASH) State-of-the-Art Symposium 2010
September 24-25, 2010
Chicago, United States
Society for the Advancement of Blood Management® (SABM®) 2010 Annual Meeting
September 24-26, 2010
San Juan, Puerto Rico
Stem Cells and Regeneration
October 3-9, 2010
Woods Hole, United States
American Association of Blood Banks (AABB) Annual Meeting 2010
October 9-12, 2010
Baltimore, United States
Fraunhofer Life Science Symposium Leipzig 2010
October 29-30, 2010
Leipzig, Germany
52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States
Highlights of American Society of Hematology (ASH) Vancouver
January 21-22, 2011
Vancouver, Canada
Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES
Cell Therapy Technologist (Opexa Therapeutics)
Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization's career opportunities with Cell Therapy News.
Visit here to post your career opportunities.
Have we missed an important article or publication in Hematopoiesis News? Click here to submit!
Comments or Suggestions? Email info@connexoncreative.com with your feedback.
|
|
|
|
|
|
|
|
|
